GlobeNewswire Inc | Jan 10, 2022 08:00AM EST

January 10, 2022

WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022. Details for the event and managements participation are as follows:

H.C. Wainwright BioConnect 2022Dates: January 10-13, 2022Format: On-demand investor presentation beginning on January 10, 1-on-1 investor meetingsFireside Chat: January 10, with link available through the event portalRegistration: www.hcwevents.com/bioconnect

About EntasisEntasis is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including post Phase 3 sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.

Entasis Contacts Company Contact Investor ContactKyle Dow Bruce MackleEntasis Therapeutics LifeSci Advisors(781) 810-0114 (929) 469-3859kyle.dow@entasistx.com bmackle@lifesciadvisors.com Media Contact Brett Whelan LifeSci Communications (215) 315 3143 bwhelan@lifescicomms.com